ACUTE DISEASE;
ARTICLE;
BARTHEL INDEX;
BRAIN INFARCTION;
CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DRUG EFFICACY;
GLASGOW OUTCOME SCALE;
HUMAN;
MAJOR CLINICAL STUDY;
NATIONAL INSTITUTES OF HEALTH STROKE SCALE;
PRIORITY JOURNAL;
RANKIN SCALE;
SINGLE BLIND PROCEDURE;
STROKE;
TREATMENT OUTCOME;
DISABILITY EVALUATION;
GLASGOW OUTCOME SCALE;
HUMANS;
NATIONAL INSTITUTES OF HEALTH (U.S.);
PREDICTIVE VALUE OF TESTS;
RECOVERY OF FUNCTION;
ROC CURVE;
SENSITIVITY AND SPECIFICITY;
SEVERITY OF ILLNESS INDEX;
STROKE;
TRAUMA SEVERITY INDICES;
TREATMENT OUTCOME;
UNITED STATES;
Baseline NIH stroke scale score strongly predicts outcome after stroke: A report of the trial of org 10172 in acute stroke treatment (TOAST)
Adams Jr. H.P., Davis P.H., Leira E.C., et al. Baseline NIH stroke scale score strongly predicts outcome after stroke: A report of the trial of org 10172 in acute stroke treatment (TOAST). Neurology 53 (1999) 126-131
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS TPA stroke trial
Broderick J.P., Lu M., Kothari R., et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS TPA stroke trial. Stroke 31 (2000) 2335-2341
Comparison of the National Institutes of Health stroke scale with disability outcome measures in acute stroke trials
Young F.B., Weir C.J., and Lees K.R. Comparison of the National Institutes of Health stroke scale with disability outcome measures in acute stroke trials. Stroke 36 (2005) 2187-2192
Using change in the National Institutes of Health stroke scale to measure treatment effect in acute stroke trials
Bruno A., Saha C., and Williams L.S. Using change in the National Institutes of Health stroke scale to measure treatment effect in acute stroke trials. Stroke 37 (2006) 920-921
Tissue plasminogen activator for acute ischemic stroke
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
Low molecular weight heparinoid, org 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators
Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, org 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial. JAMA 279 (1998) 1265-1272
Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
Ingall T.J., O'Fallon W.M., Asplund K., et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 35 (2004) 2418-2424
Confirmation of TPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-TPA stroke trials
Saver J.L., and Yafeh B. Confirmation of TPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-TPA stroke trials. Stroke 38 (2007) 414-416
